Five-Year I AM ALS Impact Report

September 20 – Update to I AM ALS statement regarding NurOwn Advisory Committee Meeting

Update to I AM ALS statement regarding NurOwn Advisory Committee Meeting

I AM ALS statement regarding the upcoming NurOwn Advisory Committee Meeting

I AM ALS calls on the FDA to allow video testimony of participants for the upcoming NurOwn AdComm hearing

I am the CEO of I AM ALS, an organization created and driven by individuals affected by ALS.

I AM ALS statement on demographic data collection

We are writing this to respond to community questions about I AM ALS’ demographic data collection. In particular, there have been several frustrations with extensive gender identity and sexual orientation response options on action forms.

NurOwn Working Group creates social media toolkit for advocates

From now until September 27, I AM ALS and the ALS community will use the template social media posts to encourage people to submit written testimony for the NurOwn AdComm and support I AM ALS’ statement on NurOwn.

I AM ALS named as a finalist for PRWeek’s 2023 Purpose Awards

I AM ALS has been named as a PRWeek 2023 Purpose Award finalist.

I AM ALS announces grant from Poarch Band of Creek Indians

I AM ALS recently received a $250,000 grant from the Poarch Band of Creek Indians.

Guide to Submitting Written Testimony to the FDA about NurOwn

The FDA invites people to submit written comments about NurOwn to the AdComm panel for their review prior to the September 27th meeting.

CBO releases much lower cost estimate for Elizabeth Dole Home Health Care Act

The Congressional Budget Office (CBO) released a new, much lower cost estimate for the Elizabeth Dole Home and Community-Based Services Act, S.141/H.R. 542.

NurOwn AdComm announced in Federal Register — what’s next?

I AM ALS State of the State, July 2023 – CEO Reflects on First 100 Days

Five things I’ve learned in my first days as CEO, from the desk of Andrea Goodman